Occidental Petroleum Eyes $10B OxyChem Sale to Reduce Debt Load

Occidental Petroleum (OXY) is reportedly seeking to divest its OxyChem subsidiary for approximately $10 billion, a strategic move aimed at substantially reducing its $23.34 billion long-term debt largely accrued from major acquisitions. This potential sale, which would significantly exceed OXY's previous asset divestiture targets, comes amidst a challenging petrochemical market characterized by oversupply and declining profits, though analysts remain cautious on OXY's outlook despite its debt reduction efforts.

Analysis

Occidental Petroleum (OXY) is pursuing a significant strategic pivot by exploring the sale of its OxyChem subsidiary for an estimated $10 billion. This move is a direct response to the company's substantial long-term debt, which stood at $23.34 billion as of June 30, 2025, largely resulting from its $55 billion acquisition of Anadarko in 2019 and the $12 billion purchase of CrownRock in 2023. A successful divestiture at this valuation would allow OXY to dramatically accelerate its deleveraging program, far exceeding its initial post-CrownRock asset sale target of $4.5 to $6 billion. However, this corporate restructuring is occurring within a challenging macro environment, as the petrochemical industry faces declining profits due to oversupply and the broader energy sector contends with lower oil prices. This market pressure is reflected in OXY's stock performance, which has declined 2.4% year-to-date, starkly underperforming peers Chevron and ExxonMobil, which have seen gains of over 14% and nearly 12% respectively. Consequently, analyst sentiment remains cautious, with a consensus 'Hold' rating and a modest average price target implying only 4.2% upside, suggesting the market views this deleveraging as a necessary but not yet transformative event.

Key Decisions for Investors

• Investors should monitor the execution and final valuation of the OxyChem sale, as a successful $10 billion transaction would be a critical catalyst for improving the company's balance sheet and credit profile.
• Given OXY's significant stock underperformance relative to peers, consider whether the deleveraging story is compelling enough to offset the headwinds from a weak petrochemical market and the company's higher debt burden.
• The cautious 'Hold' consensus from analysts and limited price target upside suggest that a wait-and-see approach may be prudent until the benefits of the divestiture are realized and there is greater clarity on the trajectory of commodity prices.